David Malcom Rodman sold $75k of MLYS
Chief Medical Officer at Mineralys Therapeutics, Inc.. 5,026 shares at an average of $15.00, traded Nov 11, 2024, filed Nov 12, 2024.
Score components
- +15RoleOfficer
- +8Trade size$75k at market
- 0Share of holdings soldSold 3.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.0%, 3m -27.8%, 6m +13.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-24-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +5,017 | $0.54 | $2,709 | 140,991 | Nov 12, 2024 |
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +5,026 | $1.08 | $5,428 | 146,017 | Nov 12, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -5,026 | $15.00 | $75k | 140,991 | Nov 12, 2024 |
| Nov 11, 2024 | MOption exercise Stock Optionderivative10b5-1 | -5,017 | $0.00 | $0 | 10,035 | Nov 12, 2024 |
| Nov 11, 2024 | MOption exercise Stock Optionderivative10b5-1 | -5,026 | $0.00 | $0 | 134,926 | Nov 12, 2024 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director, owner | $3.5M 259,259 shares | +3% | |
| 17Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $187k 15,319 shares | -2% | |
| 58Moderate | Mineralys Therapeutics, Inc. | Srinivas Akkaraju director | $8.1M 600,000 shares | +12% | |
| 61Notable | Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $17M 1,296,296 shares | +43% | |
| 16Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $166k 18,333 shares | -2% | |
| 1Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $383k 25,482 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.